16 Sep 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Latest data released by the research firm AIOCD, revealed that the Indian domestic pharma retail market experienced its lowest ever plunge with a growth of a meager 1.1 percent in August this year.
This is the first jolt the pharmaceuticals market has recorded after the implementation of the new pharma policy in the country. Previously the industry had dipped to 4.3 percent in November 2012.
Sun Pharma at 14.9 percent, Alkem at 5.9 percent and Cipla at 4.9 percent were the top performers in the month, AIOCD data said.
The DPCO 2013 containing molecules market was down by -12.3 percent, whereas the non-DPCO market grew by 3.3 percent, resulting in overall growth of 1.1 percent.
Anti-infective market has a degrowth of 1.1 percent, whereas respiratory market grew by 6.2 percent. The anti-diabetic market posted a growth of 6.4 percent, and cardiac at 4 percent in the chronic category.
Amongst the molecules with specific strengths under Drug Price Control Order 2013, Amoxycillin-Clavulanic acid degrew at 4.2 percent, Atorvastatin market dipped by 27.8 percent, Paracetamol by 20.1 percent, and Azithromycin by 18.7 percent.